Throughout the conversation about the current challenges limiting access to lifesaving treatments, I advocated for policymakers to take actions to ensure that the latest scientific advancements make their way into the hands of patients.
ICYMI: Misaligned policies undermine patient access.
Recently, I participated in the “Unlocking Access to Treatments and Medicines” panel at Bamberg Health’s U.S. Northeast Healthcare Innovation Summit, alongside Christina M. Annunziata, Senior Vice President of Extramural Discovery Science at the American Cancer Society, Hilary Marston, Chief Medical Officer at the FDA and Sawn Darshan Parekh, Chief Executive Officer of Roxborough Memorial Hospital.
Throughout the conversation about the current challenges limiting access to lifesaving treatments, I advocated for policymakers to take actions to ensure that the latest scientific advancements make their way into the hands of patients. Here are 3 takeaways from the conversation:
1. The Inflation Reduction Act jeopardizes the development of small molecule medicines which provide unique benefits to patients.
2. GLP-1s offer a prime opportunity to drive competition in our industry that lowers out-of-pocket costs for patients and drives access to medicines.
3. The biopharmaceutical industry continues to expand diversity in clinical trials and provide more patients with access to the health care they need to live happier and more productive lives.
Read more about the work we’re doing to increase access to valuable medicines and treatments here.
